Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel te ...

The glucagon pen more quickly resolved global hypoglycemia symptoms than the GEK (11.6 min vs. 13.1 min). The overall incidence of all adverse events (AEs) was comparable in both groups.

The instructions in the kit will give details of how to mix these for injection. Glucagon can be injected into the arm, thigh or buttocks. There is no danger of overdose with glucagon. Glucagon can ...

Austin-based specialty drug startup Xeris Pharmaceuticals just closed a $41 million Series C round to advance its G-Pen – a shelf-stable glucagon product for diabetics with severe hypoglycemia.

One of them that’s developed a low-volume formulation that’s stored in a two-step injectable glucagon pen is preparing for phase 2 clinical trials and looking for financing.

Xeris announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its ready-to-use glucagon rescue pen for the treatment of severe hypoglycemia ...

It will have clear instructions on how to quickly mix and inject the glucagon shot. Teach your family, roommates, or coworkers how to give you the shot in case you pass out.

Two easy-to-use new glucagon rescue products, an autoinjector pen and a prefilled syringe, have been approved in the US for use in severe hypoglycemia in diabetes patients aged 2 years and older.

Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) today announced Phase 3 data presentations on its investigational ready-to-use glucagon rescue pen.